GEROPHARM 20 March 2023 14:53
On March 19, Algeria released the first batch of insulins from the pharmaceutical substance GEROPHARM. The launch of production took place at the plant of the Algerian state pharmaceutical company "SAIDAL Industrial Group" in the presence of Nadia Bouabdella, Director of the Pharmaceutical production department of the Ministry of Industry and Pharmaceutical Production of Algeria.
The first batch was 40,000 vials of short-acting genetically engineered human insulin, and another 80,000 vials will be released by the end of the month. The entire volume of the drug will be directed to the needs of the Algerian hospital sector.
According to the IDF Diabetes Atlas, as of 2021, more than two million adult patients with diabetes mellitus have been registered in Algeria. At the same time, the proportion of residents with an undiagnosed disease is about 40%.
Taking into account the scale of the spread of the disease and the importance of providing patients with a vital drug, the President of Algeria instructed to provide 50% of the population's insulin needs by the end of 2023 at the expense of local production.
The Russian pharmaceutical company GEROPHARM assisted in the operational solution of the task by transferring the technology of production of finished dosage forms of genetically engineered human insulins to the site of the SAIDAL Group in Konstantin. The audit of the plant and staff training in Algeria and in Russia – at the GEROPHARM research center – were carried out in record time: in 2 months. Among other things, the Algerian company's specialists were given the methods of input control and output quality control.
Peter Rodionov, CEO of GEROPHARM: "Interest in Russian insulins from countries in Africa, the Middle East, Asia and Latin America is growing every year. At the same time, we see the greatest prospects for GEROPHARM and our partners in the localization of production. GEROPHARM already has a successful experience in implementing cooperation projects in this area.
With our Algerian partners, as well as with the invaluable assistance of the Russian Embassy and Trade Mission in Algeria and the Algerian Embassy in Moscow, we managed to implement the first project for us to produce Russian insulin in Africa in the shortest possible time. I am sure that this will be an important step in the development of cooperation between our countries in the strategic field of pharmaceutical production."
Fatoum Akasem, CEO of the SAIDAL Group: "Today we are especially proud to participate in the production of the first batch of human insulin at the SAIDAL plant in the Algerian city of Constantine. This important milestone is the result of a close and fruitful cooperation between SAIDAL and GEROPHARM, whose success is based on rapid and efficient technology transfer.
Our partnership will not be limited to human insulin, but will also expand to other insulin preparations in the near future. This promising alliance embodies a real success story and opens up new opportunities for cooperation between Algeria and Russia in the field of pharmaceuticals."
By the end of the year, the SAIDAL industrial group and GEROPHARM plan to expand cooperation on insulin.
Please note that this press release is based on materials provided by the company. AK&M Information Agency shall not be held liable for its contents, nor for the legal and other consequences of its publication
